The addiction research group at New Zealand’s National Institute for Health Innovation have completed two pragmatic trials of e-cigarettes for smoking cessation and two trials of cytisine for smoking cessation. They are now undertaking a trial looking at the effectiveness of combining nicotine e-cigarettes and cytisine for smoking cessation. This seminar will discuss how this program of research came about and evolved over time, the need for a health equity focus, challenges with running community based trials, and how the studies have informed practice and policy to help NZ move towards its tobacco endgame.
A/Prof Natalie Walker is a public health researcher, clinical trialist and leader of the Addiction Research program at the National Institute for Health Innovation. She is also the Associate Director of the Centre for Addiction Research at the University of Auckland. Her primary area of interest is the conduct of phase III, community-based, pragmatic clinical trials, particularly in smoking cessation. She also has research interests in alcohol consumption, cannabis use, respiratory health, and cardiovascular disease